Regorafenib (Hydrochloride)

Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively[1].

Product Specifications

CAS Number

[835621-07-3]

Product Name Alternative

BAY 73-4506 (hydrochloride)

UNSPSC

12352005

Hazard Statement

H302

Target

Autophagy; PDGFR; Raf; RET; VEGFR

Type

Reference compound

Related Pathways

Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Regorafenib-Hydrochloride.html

Concentration

10mM

Purity

99.58

Solubility

DMSO : ≥ 5.6 mg/mL|H2O : < 0.1 mg/mL

Smiles

ClC1=C(C(F)(F)F)C=C(NC(NC2=C(F)C=C(OC3=CC=NC(C(NC)=O)=C3)C=C2)=O)C=C1.Cl

Molecular Formula

C21H16Cl2F4N4O3

Molecular Weight

519.28

Precautions

H302

References & Citations

[1]Wilhelm SM, et al. Regorafenib (BAY 73-4506) : a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer, 2011, 129 (1), 245-255.|[2]Heng DY, et al. Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol, 2010, 2 (1), 39-49.|[3]Carr BI, et al. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol, 2013, 228 (2), 292-297.